<a href="https://www.fiercebiotech.com/biotech/50m-flagship-pioneering-serif-hopes-write-new-chapter-dna-medicines" hreflang="en">With $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines</a>
Serif Biomedicines, a new biotech startup backed by Flagship Pioneering with a $50 million investment, aims to revolutionize DNA medicines by developing a new class of therapeutics that are safer and more accessible than traditional gene therapies. The company focuses on using modified DNA packaged in lipid nanoparticles to avoid immune responses and improve manufacturing processes, with potential applications in protein replacement and T-cell engineering.
Serif Biomedicines, backed by a $50M investment from Flagship Pioneering, is pioneering a new category of DNA medicines that aim to be safer and more accessible than traditional gene therapies by using chemically modified DNA delivered via cell-specific lipid nanoparticles. This approach could potentially redefine therapeutic possibilities similar to monoclonal antibodies and mRNA, suggesting a significant opportunity for partnerships and pipeline expansion in the biotech sector focused on protein replacement and in vivo T-cell engineering.